(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

TCGFB, a private biotech founded by healthcare VC The Column Group, is tapping California biotech Surrozen to discover ...

Lung transplantation remains a vital option for advanced IPF, with increasing transplant numbers and evolving allocation strategies. Idiopathic pulmonary fibrosis (IPF) is characterized by a ...

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

The term “progressive pulmonary fibrosis” or “PPF” is generally used to describe progressive lung fibrosis in an individual with an interstitial lung disease (ILD) other than idiopathic ...

Identifying the underlying causes of prolonged lung inflammation associated with radiographic abnormalities could be key understanding long COVID and other lung conditions, researchers say.

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

Structure Therapeutics Inc ... Thus, a patient who has idiopathic pulmonary fibrosis has scarring/damage to the lungs with no known root cause. In essence, it just comes about randomly.

Double lung transplant recipient, Linda Paradis, is raising awareness of the importance of organ donation, as she now needs a kidney.

Cumberland Pharmaceuticals Inc. , a specialty pharmaceutical company, announced today that the United States (U.S.) Food and Drug Administration (FDA) granted Orphan Drug Designation and Rare ...